Comparison between Crizac IPO and Paramesu Biotech IPO.
Crizac IPO is a Mainboard Bookbuilding IPO proposed to list at BSE, NSE while Paramesu Biotech IPO is a Mainboard Bookbuilding proposed to list at BSE, NSE.
The total issue size of Crizac IPO is up to ₹860.00 Cr whereas the issue size of the Paramesu Biotech IPO is up to ₹600.00 Cr. The final issue price of Crizac IPO is ₹245.00 per share and of Paramesu Biotech IPO is .
| Crizac IPO | Paramesu Biotech IPO | |
|---|---|---|
| Face Value | ₹2 per share | ₹5 per share |
| Issue Price (Lower) | ₹233.00 per share | |
| Issue Price (Upper) | ₹245.00 per share | |
| Issue Price (Final) | ₹245.00 per share | |
| Discount (Retail) | ||
| Discount (Employee) | ||
| Market Lot Size | 61 shares | |
| Fresh Issue Size | 0 shares | 0 shares |
| Fresh Issue Size (Amount) | up to ₹0.00 Cr | up to ₹520.00 Cr |
| OFS Issue Size | 3,51,02,040 shares | 0 shares |
| OFS Issue Size (Amount) | up to ₹860.00 Cr | up to ₹80.00 Cr |
| Issue Size Total | 3,51,02,040 shares | 0 shares |
| Issue Size Total (Amount) | up to ₹860.00 Cr | up to ₹600.00 Cr |
Crizac IPO opens on Jul 02, 2025, while Paramesu Biotech IPO opens on . The closing date of Crizac IPO and Paramesu Biotech IPO is Jul 04, 2025, and , respectively.
| Crizac IPO | Paramesu Biotech IPO | |
|---|---|---|
| Anchor Bid Date | Jul 01, 2025 | |
| Issue Open | Jul 02, 2025 | |
| Issue Close | Jul 04, 2025 | |
| Basis Of Allotment (Tentative) | Jul 07, 2025 | |
| Initiation of Refunds (Tentative) | Jul 08, 2025 | |
| Credit of Share (Tentative) | Jul 08, 2025 | |
| Listing date (Tentative) | Jul 09, 2025 | |
| Anchor Lockin End date 1 | Aug 05, 2025 | |
| Anchor Lockin End date 2 | Oct 04, 2025 |
Crizac IPO P/E ratio is 28.03, as compared to Paramesu Biotech IPO P/E ratio of .
| Crizac IPO | Paramesu Biotech IPO | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Proforma Consolidated)Crizac Ltd.'s revenue increased by 16% and profit after tax (PAT) rose by 29% between the financial year ending with March 31, 2025 and March 31, 2024.
| Company Financials (Restated)
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 100 | 92.19 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 79.94 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 28.03 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹4287.07 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 30.24% | 23.30% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 40.03% | 18.13% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹8.74 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 30.24% | 23.30% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Crizac IPO Retail Individual Investors (RII) are offered 1,22,85,714 shares while in Paramesu Biotech IPO retail investors are offered 1,22,85,714 shares. Qualified Institutional Buyers (QIB) are offered 70,20,407 shares in Crizac IPO and 0 shares in Paramesu Biotech IPO.
| Crizac IPO | Paramesu Biotech IPO | |
|---|---|---|
| Anchor Investor Reservation | 1,05,30,612 shares | |
| Market Maker Reservation | 0 shares | 0 shares |
| QIB | 70,20,407 shares | 0 shares |
| NII | 52,65,306 shares | 0 shares |
| RII | 1,22,85,714 shares | 0 shares |
| Employee | 0 shares | |
| Others | ||
| Total | 3,51,02,040 shares | 0 shares |
Crizac IPO subscribed 62.89x in total, whereas Paramesu Biotech IPO subscribed .
| Crizac IPO | Paramesu Biotech IPO | |
|---|---|---|
| QIB (times) | 141.27x | |
| NII (times) | 80.07x | |
| Big NII (times) | 92.95x | |
| Small NII (times) | 54.32x | |
| RII (times) | 10.74x | |
| Employee (times) | ||
| Other (times) | ||
| Total (times) | 62.89x |
